Bone Marrow Transplant 2002 Jan;29(1):81-5
Oyama Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK.
Northwestern University School of Medicine, Division of Immune Therapy and Autoimmune Disease, Chicago, IL, USA.
Autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated as a therapy for patients with progressive multiple sclerosis (MS) at risk of debilitating neurological impairment.
While preliminary results from a few studies have been reported, little is known about toxicities or outcome of HSCT for MS.
We report a relatively frequent triad of non-infectious fever, rash and fatigue or lassitude that may also be associated with pruritis, pulmonary symptoms, and eosinophilia and frequently occurs around engraftment.
This syndrome occurred in 26% of our series of patients (5/19) undergoing HSCT for multiple sclerosis.
The engraftment syndrome is usually self-limited but may require intervention with systemic corticosteroids.